Novartis to buy pharmaceutical group AAA for US$3.9b
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Zurich
NOVARTIS is buying French-based Advanced Accelerator Applications (AAA) for US$3.9 billion, giving the Swiss drugmaker a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.
The cash offer of US$41 per ordinary share and US$82 per American depositary share represents a 47 per cent premium to AAA's price before media reports on Sept 27 that Novartis was interested. The ADS closed on Friday at US$72.91 and were priced at only US$16 when they listed two years ago.
Share with us your feedback on BT's products and services
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
